sur EUROMEDIS GROUPE (EPA:ALEMG)
Euromedis Group: 2024 Annual Results
The Euromedis Group Board of Directors closed the accounts for the 2024 financial year on April 25, 2025. The year was marked by the liquidation of the Gaillard Group, resulting in a €6 million impairment charge recorded as exceptional expenses. Despite this, revenue increased by 6% to €36.2 million. However, net income plunged to -€6.1 million.
The company has suffered from volatile transportation costs, particularly due to geopolitical tensions in the Middle East. These factors have lengthened supply lead times and increased cost volatility. In 2025, Euromedis is seeking to diversify its activities, with a focus on exports to reduce its reliance on public procurement.
The logistics reorganization initiated in 2024 is expected to generate savings. However, profitability in 2025 will depend on global geopolitical developments.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EUROMEDIS GROUPE